Calithera Biosciences (CALA) Stock Forecast, Price & News

Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions

Is Calithera Biosciences a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Calithera Biosciences stock.
View analyst ratings for Calithera Biosciences or view top-rated stocks.

Are investors shorting Calithera Biosciences?

Calithera Biosciences saw a decrease in short interest in April. As of April 30th, there was short interest totaling 1,600,000 shares, a decrease of 37.0% from the April 15th total of 2,540,000 shares. Based on an average daily trading volume, of 2,290,000 shares, the short-interest ratio is currently 0.7 days.
View Calithera Biosciences' Short Interest.

When is Calithera Biosciences' next earnings date?

Calithera Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Calithera Biosciences.

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences, Inc. (NASDAQ:CALA) released its quarterly earnings results on Tuesday, May, 10th. The biotechnology company reported ($0.18) EPS for the quarter, hitting the consensus estimate of ($0.18). During the same quarter last year, the business posted ($0.28) earnings per share.
View Calithera Biosciences' earnings history.

What price target have analysts set for CALA?

4 brokerages have issued twelve-month price targets for Calithera Biosciences' stock. Their forecasts range from $1.50 to $4.00. On average, they expect Calithera Biosciences' stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 977.6% from the stock's current price.
View analysts' price targets for Calithera Biosciences or view top-rated stocks among Wall Street analysts.

Who are Calithera Biosciences' key executives?

Calithera Biosciences' management team includes the following people:

• Dr. Susan M. Molineaux Ph.D., Founder, CEO, Pres & Director (Age 68, Pay $806.95k)
• Ms. Stephanie Wong, CFO & Sec. (Age 48)
• Ms. Sumita Ray J.D., Chief Legal & Admin. Officer (Age 47)
• Dr. Eric B. Sjogren, Sr. VP of Drug Discovery (Age 65)
• Dr. Christopher J. Molineaux Ph.D., Sr. VP of Devel. (Age 69)
• Mr. Frank Parlati, Sr. VP of Research (Age 53)
• Dr. Emil T. Kuriakose M.D., Chief Medical Officer
• Dr. Susan B. Demo Ph.D., Sr. VP of R&D Operations
• Dr. Allison Dillon Ph.D., Sr. VP of Commercial & Portfolio Strategy

Who are some of Calithera Biosciences' key competitors?

Some companies that are related to Calithera Biosciences include Lumos Pharma (LUMO), Lantern Pharma (LTRN), MEI Pharma (MEIP), ABVC BioPharma (ABVC), InflaRx (IFRX), Akebia Therapeutics (AKBA), 89bio (ETNB), DiaMedica Therapeutics (DMAC), Oncolytics Biotech (ONCY), Mereo BioPharma Group (MREO), iBio (IBIO), Bolt Biotherapeutics (BOLT), BioLineRx (BLRX), Qilian International Holding Group (QLI) and Longboard Pharmaceuticals (LBPH).
View all of CALA's competitors.

What other stocks do shareholders of Calithera Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), First Solar (FSLR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE).

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Who are Calithera Biosciences' major shareholders?

Calithera Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.71%), Acadian Asset Management LLC (2.51%), Renaissance Technologies LLC (2.35%), Affinity Asset Advisors LLC (1.27%), Alyeska Investment Group L.P. (1.27%) and Empery Asset Management LP (0.99%). Company insiders that own Calithera Biosciences stock include Bvf Partners L P/Il, Keith Orford and Susan Molineaux.
View institutional ownership trends for Calithera Biosciences.

Which institutional investors are selling Calithera Biosciences stock?

CALA stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., GSA Capital Partners LLP, Virtu Financial LLC, and HAP Trading LLC.
View insider buying and selling activity for Calithera Biosciences or view top insider-selling stocks.

Which institutional investors are buying Calithera Biosciences stock?

CALA stock was acquired by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Affinity Asset Advisors LLC, Empery Asset Management LP, Renaissance Technologies LLC, Truist Financial Corp, Bailard Inc., Acadian Asset Management LLC, and TSP Capital Management Group LLC.
View insider buying and selling activity for Calithera Biosciences or or view top insider-buying stocks.

How do I buy shares of Calithera Biosciences?

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Calithera Biosciences' stock price today?

One share of CALA stock can currently be purchased for approximately $0.23.

How much money does Calithera Biosciences make?

Calithera Biosciences has a market capitalization of $18.26 million and generates $9.75 million in revenue each year. The biotechnology company earns $-115.09 million in net income (profit) each year or ($1.440010) on an earnings per share basis.

How many employees does Calithera Biosciences have?

Calithera Biosciences employs 92 workers across the globe.

What is Calithera Biosciences' official website?

The official website for Calithera Biosciences is www.calithera.com.

How can I contact Calithera Biosciences?

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (650) 870-1000 or via email at [email protected].